A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship

Erlangga Yusuf, Markus Zeitlinger, Sylvain Meylan

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

The interpretation of 'susceptible (S)' or 'resistant (R)' results of antimicrobial susceptibility testing is easily understood, but the interpretation of the 'intermediate (I)' category can be confusing. This review critically discusses how this categorization (clinical breakpoints) comes into being with the emphasis on the use of pharmacokinetics and pharmacodynamic data. It discusses the differences between the 'I' according to the CLSI and the EUCAST. This review also discusses the recent EUCAST change of the 'I' definition, and the impact of this change from laboratory and clinical points of view.

Original languageEnglish
Pages (from-to)338-345
Number of pages8
JournalThe Journal of antimicrobial chemotherapy
Volume78
Issue number2
DOIs
Publication statusPublished - 1 Feb 2023

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: [email protected].

Funding Information:
This study was carried out as part of our routine work.

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved.

Fingerprint

Dive into the research topics of 'A narrative review of the intermediate category of the antimicrobial susceptibility test: relation with dosing and possible impact on antimicrobial stewardship'. Together they form a unique fingerprint.

Cite this